Vanguard Capital Management
PMCB icon

Vanguard Capital Management’s PharmaCyte Biotech PMCB Stock Holding History

Vanguard Capital Management’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.7K Buy
56,778
+5,311
+10% +$4K ﹤0.01% 3947
2026
Q1 		$34.2K Buy
+51,467
New +$39.4K ﹤0.01% 3952

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Vanguard Capital Management's PMCB Position: Q2 2026 in Review

Vanguard Capital Management increased its PharmaCyte Biotech (PMCB) stake by 10% in Q2 2026, buying an estimated $4K and bringing the position to 56,778 shares worth $43.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3947.

Vanguard Capital Management first reported a position in PMCB in Q1 2026 and has held it in 2 quarters since. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Vanguard Capital Management held 56,778 shares of PharmaCyte Biotech worth $43.7K as of Q2 2026.
  • Vanguard Capital Management bought 5,311 PharmaCyte Biotech shares in Q2 2026, an estimated $4K.
  • PharmaCyte Biotech made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3947 holding.
  • Vanguard Capital Management first reported a position in PharmaCyte Biotech in Q1 2026 and has held it in 2 quarters since.
  • 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.